Gufic Biosciences share news, announcements and annual reports
NSE: GUFICBIOBSE: 509079Pharmaceuticals & BiotechnologySmall Cap
Gufic Biosciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1985 on BSE, Oct 2004 on NSE
Last close ₹423.75up ₹3.30 (0.78%)BSE ₹423.70
Share price at the NSE close on 28 Oct 2026. Previous close ₹420.45.
28 Oct: open ₹420.95, high ₹430.70, low ₹414.15
52-week range of traded prices to 28 Oct 2026
₹268.00Low, 9 Mar 2026₹467.80High, 7 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,249 Cr959th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 57.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,56,95560.7% delivered
Gufic Biosciences share news and announcements
608 announcements, routine notices left out, newest first. Page 13 of 13.
Oct 2007
22 Oct · Board meeting
Meeting on 31 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”9 Oct · Management
Vide its letter dated October 08, 2007 that : "Dr. M.G. Dhapalapur has been appointed as Director of the Company on the Board of Directors of the Company with effect from 1st August 2007."
Jul 2007
17 Jul · Board meeting
Meeting on 31 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
Jun 2007
28 Jun · Management
Mr. Vijay Agarwal has tendered his resignation as Director from the Board of Directors of the Company with effect from 25th June 20078 Jun · Limited Review Report
Auditor's have conducted the limited review of the unaudited financial results for the quarter ended March 31, 2007 and found the same to be in order subject to certain observations. The auditor's observations are: "We are unable to express our opinion on the recoverability and consequently provision of the specific debts outstanding for more than one year, aggregating to Rs. 249.87 lacs, However, in the opinion of the management, the same are good and recoverable and thus no provision in respect thereof ".
Apr 2007
23 Apr · Board meeting
Meeting on 30 Apr 2007: “Unaudited Financial Results for the Qtr ended March 31, 2007”
Mar 2007
19 Mar · Limited Review Report
Auditor's have conducted the limited review of the unaudited financial results for the quarter ended December 31, 2006 and found the same to be in order subject to certain observations. The auditor's observations are that "we are unable to express our opinion on the recoverability and consequently provision of the debts, aggregating to Rs. 379.67 lacs, pertaining to debts outstanding for more than one year."
Jan 2007
23 Jan · Board meeting
Meeting on 31 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”